Resultados de Búsqueda

Evidencias COVID-19

Cochrane - Colección Especial - medidas de prevención y control de la infección

Multimodal strategies (combinations) that include some but not all of the WHO recommended strategies may slightly improve compliance with hand hygiene and slightly reduce infection rates. It is urgently needed methodologically consistent research to explore the effectiveness of multimodal versus simpler interventions in increasing hand hygiene compliance. Information on hygiene practices can improve compliance with hand hygiene (low certainty of the evidence) and is likely to slightly reduce ...

Evidencias COVID-19

Cochrane - Colección Especial - Cuidados Críticos (asistencia respiratoria y ventilación mecánica)

We found no evidence that high-flow nasal cannulae (HFNC) reduced the rate of treatment failure or risk of death compared with low‐flow oxygen devices. We found no evidence of any advantages for HFNC in terms of adverse event rates, Intensive Care Unit (ICU) length of stay, or duration of respiratory support. We observed no differences in participants' blood oxygen levels or carbon dioxide blood levels, and we noted that any differences in breathing rates were small and were not considered ...

Evidencias COVID-19

Coronavirus (COVID-19): Evidence Collection. Evidence Aid

COVID-19 is an infection of the respiratory tract. It has been suggested that Vitamin D supplementation might prevent acute respiratory tract infection in other circumstances. The findings of research into this may be worth considering for COVID-19. In this systematic review, the authors collected data on each individual participant in randomised, placebo controlled trials of supplementation with vitamin D3 to evaluate its effects on the prevention of acute respiratory tract infection. They ...

NICE

National Institute for Health and Clinical Excellence (NICE)

This guidance is not intended to affect the position of patients whose treatment with etelcalcetide was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.

NICE

National Institute for Health and Clinical Excellence (NICE)

These recommendations are not intended to affect treatment with asfotase alfa that was started in the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. For children and young people, this decision should be made jointly by the clinician and the child or young person or the ...